BONUS BIOGROUP (TASE: BONS) is a biotechnology company applying proprietary, innovative technology to supply tissue-engineered viable bone grafts. The company strives to become a world leader in the field of tissue engineering and live bone transplantation.

 

 

 

 

Bonus Biogroup Ltd (TASE:BONS)

 

 

To all News >

 

 

Bonus BioGroup has developed a novel method to grow bone grafts from cells derived from the patient's fat tissue. The graft is precisely fit to the injured bone site and rapidly integrates in the patient's body.

 

 

BonoFill^TM products family

Exclusive 3D, high-density bone grafts, grown from the cells derived from the patient's fat tissue, obtained in a simple procedure. Heterogeneous population of cells are then cultured and expanded in a bioreactor system, on a supportive matrix (scaffold), and induced to generate the bone graft. The graft is precisely fit to the injured bone site and rapidly integrates in the patient's body.

 

 

	Injectable bone graft Appropriate for defined defects, such as maxillofacialbone voids and cysts.		Anatomically pre-designed bone graft A cut to shape graft, match the dimensions of the patient's bone gap, determine using CT imaging

Read more  >    Bono FillTM  |   Product pipeline 

Clinical Trial In April 2014, Bonus BioGroup commenced a clinical trial designed to test the safety and efficacy of the injectable BonoFillTM product in the repair of human maxillofacial bone deficiency, including upper or lower jawbone cavitation.

 

Read more  >   Clinical trial   |  Manufacturing facility 

 

 

Bone reconstruction is medically required to repair an injured bone arise in a multitude of situations of trauma and bone diseases. The ideal bone graft is biocompatible, functionally and structurally similar to the patient's bone, easily transplantable and cost-effective. Failure rates of current techniques have encouraged researchers to seek new biomaterials promoting bone regeneration.

 

Read more  >  Bone regeneration  |   Tissue engineering

 

Adipose tissue has significant advantages as a cell source for tissue engineering products. Human Adipose Tissue-Derived Cells (HATDCs) can differentiate along multiple cell lineage pathways to form various types of mature cells, and can be safely and effectively transplanted back into the patient.     Read more  >    Human Adipose tissue derived cells (HATDCs)